A New Immunological Test for Alzheimer’s Disease

The p-tau217 marker is currently considered the most relevant blood biomarker in Alzheimer’s disease. However, the availability of tests remains limited in both research and clinical settings. In this study, researchers evaluated the relevance of a new immunological test to measure plasma p-tau217. The test was used on three cohorts of participants (a total of 786 participants, 64.1% of whom were women), with or without cognitive impairment, categorized according to their amyloid and tau status using PET or CSF biomarkers. The test proved to be relevant, with data comparable to those obtained with CSF biomarkers. Researchers detected longitudinal changes, including at the preclinical stage of Alzheimer’s disease.